18F-Fluciclovine PET/CT Superior to 11C-Choline PET/CT for the Detection of a Prostate Cancer Relapse

We have all been ever increasingly aware of the weakness of our scanning technologies when it comes to both diagnosing prostate cancer and its recurrence. Given that about 1/3 of all primary treatments for prostate cancer will fail and the cancer will return it is vital that we improve our ability to detect prostate cancer [...]

Decatur Memorial Hospital Now Offers A C-11 Choline PET CT To Men With Recurrent Prostate Cancer

According to a press release from the Decatur Memorial Hospital in Decatur Ill., after their having completed a clinical trial evaluating C-11 Choline PET CT and in men who have suffered a biochemical relapse of prostate cancer, they are now offering the C-11 Choline PET CT commercially. C-11 Choline uses an FDA approved tracer which, [...]

Better Predicting Advanced Prostate Cancer Outcomes with NaF-PET/CT Scans

Imaging of prostate cancer has been improving by leaps and bounds over the last few years. Current imaging techniques are not sensitive enough to give us an accurate picture of the cancer. This means that we lose predictive abilities and don’t always have adequate information to make the best treatment decisions. It also means, in [...]

Comparing (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) and (11)C-choline PET/CT in Prostate Cancer Relapse

There has been a lot of hype and confusion about what is the best contrast for prostate cancer PET/CT scans. The two newest contrasts; (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) and (11)C-choline both have their supporters and their detractors. To try and evaluate the efficacy differences between these two contrasts in men who have suffered a bio-chemical recurrence [...]

Quality Control Of Xofigo – Confirming That Intravenous Radium-223 Actually Becomes Systemic and Doesn’t Leak At The Injection Site

Radium-223 dichloride (Xofigo) has been approved as an intravenous radiotherapy for men with castration-resistant prostate cancer (CRPC) who have multiple osseous (bone) metastases. Most often, it is used in men who have too many metastases to treat with spot radiation. Xofigo works by mimicking calcium that is attracted to bones. To be successful the drug [...]

Go to Top